ArticleJournal of inflammation research2026
Exploring the Mechanism of Therapeutic Effects of Polydatin in Lung Ischemia-Reperfusion Injury by Network Pharmacology and Experiment Validation.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To elucidate the therapeutic mechanism of polydatin against lung ischemia-reperfusion injury (LIRI), this study adopted an integrated strategy combining network pharmacology with experimental verification. Methods: Potential targets of polydatin were retrieved from TCMSP, PubChem, SwissTargetPrediction, and Herb. LIRI-related targets were were collected from GeneCards, OMIM, and TTD. Venn analysis was used to identify common targets. A protein-protein interaction (PPI) network was constructed using STRING and analyzed with Cytoscape (CytoNCA plugin).Enrichment analyses (GO/KEGG) were performed to identify key pathways. For experimental validation, an in vitro LIRI model was established in human alveolar epithelial A549 cells undergoing hypoxia/reoxygenation (H/R). The protective effects and associated mechanisms of polydatin were then evaluated through multiple assays, including CCK-8 assay, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), ELISA, TUNEL staining, and reactive oxygen species (ROS) detection. Meanwhile, the activity of superoxide dismutase (SOD) and the level of malondialdehyde (MDA) were quantified. Results: Network pharmacology identified 199 potential common targets, with top 10 core ones including AKT1, IL6, TNF, ALB, TP53, INS, IL1B, STAT3, EGFR, and BCL2. GO/KEGG analyses indicated polydatin's protective effects may relate to inflammatory response modulation, apoptotic signaling regulation, and NF-κB pathway involvement. Experimentally, polydatin enhanced H/R-injured A549 cell viability, reduced apoptosis, increased SOD activity, and decreased MDA, ROS, and inflammatory cytokines (IL-6, IL-1β, TNF-α). It also upregulated AKT1 and ALB mRNA and downregulated TP53 mRNA. Conclusion: Collectively, our results indicate that polydatin alleviates LIRI by attenuating oxidative stress, inflammation, and apoptosis, likely via multi-target and multi-pathway mechanisms centered on key hubs such as AKT1, IL6, TNF, ALB, TP53, and the NF-κB pathway. This study provides a theoretical and experimental basis for further exploration of polydatin as a potential LIRI treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.